Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Resonance Health Ltd ( (AU:RHT) ) has provided an announcement.
Resonance Health Ltd has announced its intention to release its full-year results for FY25 and guidance for FY26 on the ASX by 29 August 2025. The company will host a webinar for investors and analysts to discuss these results, encouraging stakeholder engagement through interactive participation. This announcement reflects Resonance Health’s commitment to transparency and stakeholder communication, potentially impacting its market positioning and investor relations.
More about Resonance Health Ltd
Resonance Health is an Australian healthcare technology and services company providing globally recognized quantitative assessments for managing diseases and drug development. The company offers Software-as-Medical Devices (SaMDs) with regulatory clearances in the USA, Europe, UK, and Australia, including products like FerriScan®, FerriSmart®, HepaFatScan®, HepaFatSmart®, LiverSmart®, and CardiacT2*. Resonance Health also manages clinical trials and holds ISO 13485 certification for medical device design and manufacture.
Average Trading Volume: 213,597
Technical Sentiment Signal: Sell
Current Market Cap: A$17.89M
See more data about RHT stock on TipRanks’ Stock Analysis page.